Lonza Prices EUR 700 Million and USD 200 Million Multi Tranche “Schuldschein” Loan

Basel, Switzerland, 4 August 2017 – Lonza Group Ltd, Basel (“Lonza”), today announced the pricing of its multi-tranche "Schuldschein" loan (private placement) with a total size of EUR 700 million and USD 200 million at competitive market terms. The EUR tranches have maturities of 4 and 6 years respectively with fixed and variable coupons. The USD tranches have maturities of 5 (variable coupon) and 7 years (fixed coupon).

The proceeds of the “Schuldschein” loan will be used for the refinancing of the Capsugel acquisition. Commerzbank, Helaba, HSBC, ING Bank, and LBBW have jointly acted as arrangers of the “Schuldschein” loan.

About Lonza
Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at
Return Home